3WIN NV
This article was originally published in Start Up
Executive Summary
Technology originally developed for one of the most sophisticated and advanced active implantable medical devices - cochlear implants - has been key to the development of 3WIN NV's deep brain stimulation device. The Flemish start-up's neurostimulator Synapse is designed to reduce collateral stimulation through the precise delivery of an electrical charge; as well as record the neural response to better target therapy for movement disorders.
You may also be interested in...
Start-Up Previews
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Respiratory Therapies: Moving Beyond Symptomatic Relief," features profiles of Pearl Therapeutics, Protectimmun and Pulmatrix. Plus these Start-Ups Across Health Care: 3WIN, Cianna Medical, GlySure and Promedior.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.